Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response

Journal Article · · Cell Host & Microbe
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; « less
SARS-CoV-2 infection causes diverse outcomes ranging from asymptomatic infection to respiratory distress and death. A major unresolved question is whether prior immunity to endemic, human common cold coronaviruses (hCCCoVs) impacts susceptibility to SARS-CoV-2 infection or immunity following infection and vaccination. Therefore, we analyzed samples from the same individuals before and after SARS-CoV-2 infection or vaccination. We found hCCCoV antibody levels increase after SARS-CoV-2 exposure, demonstrating cross-reactivity. However, a case-control study indicates that baseline hCCCoV antibody levels are not associated with protection against SARS-CoV-2 infection. Rather, higher magnitudes of pre-existing betacoronavirus antibodies correlate with more SARS-CoV-2 antibodies following infection, an indicator of greater disease severity. Additionally, immunization with hCCCoV spike proteins before SARS-CoV-2 immunization impedes the generation of SARS-CoV-2-neutralizing antibodies in mice. Together, these data suggest that pre-existing hCCCoV antibodies hinder SARS-CoV-2 antibody-based immunity following infection and provide insight on how pre-existing coronavirus immunity impacts SARS-CoV-2 infection, which is critical considering emerging variants.
Research Organization:
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
Sponsoring Organization:
USDOE Laboratory Directed Research and Development (LDRD) Program
Contributing Organization:
SJTRC Study Team
Grant/Contract Number:
89233218CNA000001
OSTI ID:
2584674
Report Number(s):
LA-UR--21-30006; 10.1016/j.chom.2021.12.005
Journal Information:
Cell Host & Microbe, Journal Name: Cell Host & Microbe Journal Issue: 1 Vol. 30; ISSN 1931-3128
Publisher:
ElsevierCopyright Statement
Country of Publication:
United States
Language:
English

References (49)

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses journal March 2021
COVID-19-neutralizing antibodies predict disease severity and survival journal January 2021
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection journal April 2021
Harnessing immune history to combat influenza viruses journal August 2018
Immune history and influenza virus susceptibility journal February 2017
SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection journal June 2021
Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1) journal April 2021
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets journal June 2021
From Original Antigenic Sin to the Universal Influenza Virus Vaccine journal January 2018
Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19 journal June 2021
Molecular Evolution of Human Coronavirus Genomes journal January 2017
Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies journal June 2021
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike journal October 2020
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells journal July 2021
Molecular signatures of antibody responses derived from a systems biology study of five human vaccines journal December 2013
SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans journal July 2017
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity journal January 2021
Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity journal February 2021
Systems serology detects functionally distinct coronavirus antibody features in children and elderly journal April 2021
Immunological imprinting of the antibody response in COVID-19 patients journal June 2021
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses journal August 2021
The potential danger of suboptimal antibody responses in COVID-19 journal April 2020
A perspective on potential antibody-dependent enhancement of SARS-CoV-2 journal July 2020
A serological assay to detect SARS-CoV-2 seroconversion in humans journal May 2020
Seasonal coronavirus protective immunity is short-lasting journal September 2020
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study journal January 2021
circlize implements and enhances circular visualization in R journal June 2014
Complex heatmaps reveal patterns and correlations in multidimensional genomic data journal May 2016
Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection journal December 2020
Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection journal October 2020
The Doctrine of Original Antigenic Sin: Separating Good From Evil journal April 2017
Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya journal March 2018
Antibody landscapes after influenza virus infection or vaccination journal November 2014
Broad neutralization of SARS-related viruses by human monoclonal antibodies journal June 2020
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity journal September 2020
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans journal November 2020
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans journal December 2020
S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit journal October 2020
SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike journal February 2021
Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity journal October 2020
Mucosal Immune Responses Predict Clinical Outcomes during Influenza Infection Independently of Age and Viral Load journal February 2014
Recent endemic coronavirus infection is associated with less-severe COVID-19 journal January 2021
Seasonal coronavirus–specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 journal November 2021
Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI journal October 2011
Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration journal August 2021
Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection journal August 2021
Welcome to the Tidyverse journal November 2019
seaborn: statistical data visualization journal April 2021
Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study journal July 2021

Similar Records

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
Journal Article · Thu Feb 17 23:00:00 EST 2022 · Science Immunology · OSTI ID:1907939

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Journal Article · Thu Apr 15 00:00:00 EDT 2021 · Cell Host & Microbe · OSTI ID:1810870